Bio Farma

TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT TEAM RECEIVES 2023 DAVID AND BEATRIX HAMBURG AWARD FOR VACCINE TECHNOLOGY DEVELOPMENT

Retrieved on: 
Thursday, September 28, 2023
Vaccine, Texas Children's Hospital, Partnership, Tropical medicine, COVID-19, Baylor University, Biomedical Research, Brooklyn Hospital Center, Infection, Biology, AAAS David and Betty Hamburg Award for Science Diplomacy, Bio Farma, National academy, National Academy of Medicine, IndoVac, National school, Baylor College of Medicine, Corbevax, Hospital, Health, Technology transfer, Disease, Pharmaceutical industry, Dentistry, DRS, Medicine

HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the Texas Children's Hospital Center for Vaccine Development team has been awarded the 2023 David and Beatrix Hamburg Award for their development of a recombinant protein-based COVID-19 vaccine technology, created in Houston, which has benefited millions of people around the world.

Key Points: 
  • HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the Texas Children's Hospital Center for Vaccine Development team has been awarded the 2023 David and Beatrix Hamburg Award for their development of a recombinant protein-based COVID-19 vaccine technology, created in Houston, which has benefited millions of people around the world.
  • "This recognition reinforces the importance of fostering exceptional, creative and interdisciplinary scientific teams to advance biomedical sciences that benefit humanity."
  • In India, the vaccine is produced under the name Corbevax by Biological E. Limited.
  • Botswana has also approved Corbevax and the Texas Children's team is further assisting with vaccine development capacity in Africa through a training program for scientists.

Bio Farma secures multi-year Purchase Contract from UNICEF for its novel Oral Polio Vaccine type 2 (nOPV2)

Retrieved on: 
Sunday, October 2, 2022
EUA, Indonesian Ulema Council, Food, UNICEF, COVID-19, World, G20, World Health Organization, Vaccination, Pharmacy, PEHA, Certification, Laboratory, Bio Farma, Vaccine, Public health, EUL, BMGF, PATH, Emergency Use Authorization, WHO, OPV, IDX, Bill & Melinda Gates Foundation, Oral polio vaccine AIDS hypothesis, Animal, Pharmaceutical industry, Radical honesty

BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.

Key Points: 
  • BANDUNG, INDONESIA, Oct 2, 2022 - (ACN Newswire) - PT Bio Farma (Persero), the holding company for pharmaceutical state-owned enterprises (SOEs), will export its novel Oral Polio Vaccine type 2 (nOPV2) having secured a purchase contract with the United Nations Children's Fund (UNICEF) for 2022 & 23.
  • Under the contract, Bio Farma will export its oral polio vaccines based on purchase requests from UNICEF via multilateral contract agreement for the years 2022 & 23.
  • Honesti Basyir, President Director of Bio Farma, said, "UNICEF procures nOPV2 under a multilateral supply agreement as part of a global effort to prevent spread of the polio disease.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like the Bill and Melinda Gates Foundation (BMGF), the PATH, and the WHO.

TEXAS-DEVELOPED PATENT-FREE COVID-19 VACCINE TECHNOLOGY RECEIVES EMERGENCY USE AUTHORIZATION IN INDONESIA

Retrieved on: 
Friday, September 30, 2022
Certification, Bio Farma, Health, Baylor, HMO, COVID-19, Tropical medicine, Twitter, Jan, KAEF, Hospital, Pediatrics, Texas Children's Hospital, Kings County Hospital Center, View, News, Halal certification in the Philippines, Baylor University, Partnership HealthPlan of California, Vaccine, Baylor College of Medicine, INAF, Research, Pharmacy, National school, CVD, Multimedia, Urgent care center, Education, Pharmaceutical industry, Woman

Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.

Key Points: 
  • Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.
  • Indonesia is seeking Halal Certification for the vaccine since no animal cells or products were used in the production of the vaccine.
  • The pharmaceutical company is currently manufacturing Covid-19 primary series vaccine, while booster vaccine is in the clinical trial stage and soon followed by vaccine for children.
  • Bio Farma became a holding company after a merger of three listed state-owned pharmaceutical companies in Indonesia.

Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines

Retrieved on: 
Sunday, September 11, 2022
Medical school, Congo, Virus, World, Emergency, Certification, Laboratory, EUL, Ministry of Law and Human Rights, COVAX, Communication, EUA, Food, UNICEF, Child, BMGF, Directorate, Pentavalent vaccine, Bio, DGIP, Ageing, Bill & Melinda Gates Foundation, Patent, COVID-19, Faculty, Hearing, Ministry of Law, Udayana University, Emergency Use Authorization, Vaccine, Public health, WHO, Oral polio vaccine AIDS hypothesis, Baylor College of Medicine, Intellectual property, World Health Organization, Democratic republic, Bio Farma, Representative, House, PATH, Documentation, Pharmaceutical industry, Medicine, Radical honesty

After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.

Key Points: 
  • After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.
  • All Covid-19 vaccines made by Bio Farma, including the primary series vaccines, booster vaccines and vaccines for children, will be labelled IndoVac.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like Bill and Melinda Gates Foundation (BMGF), PATH and the WHO.
  • Bio Farma has since become the main supplier of polio vaccines in the world, and currently contributes 67 percent to the global supply of polio vaccines.

Sinovac Signs Agreement with Bio Farma Indonesia for COVID-19 Vaccine Cooperation

Retrieved on: 
Tuesday, August 25, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Medicine, Sinovac Biotech, Health, COVID-19 vaccine, Bio Farma, Vaccine

Under the said agreements, Sinovac is committed to supply Bio Farma bulk vaccine to enable the latter to produce at least 40 million doses of CoronaVac in Indonesia before March 2021; after March 2021, Sinovac will continue to supply the required quantity of the bulk vaccine until the end of 2021.

Key Points: 
  • Under the said agreements, Sinovac is committed to supply Bio Farma bulk vaccine to enable the latter to produce at least 40 million doses of CoronaVac in Indonesia before March 2021; after March 2021, Sinovac will continue to supply the required quantity of the bulk vaccine until the end of 2021.
  • Sinovac recognizes Indonesia as one of the countries where Sinovac will provide the technology licensing in respect of the CoronaVac to enable local production.
  • Currently, Bio Farma is conducting the Phase III Clinical Trial for Sinovacs CoronaVac in Bandung, Indonesia.
  • The cooperation between Sinovac and Bio Farma will not only further the development, production and technology licensing of the COVID-19 vaccine, but also facilitate the cooperation of the two companies in the future in the biopharmaceutical field.

INDONESIA: Finding the Right Momentum for 'BUMN Go Global'

Retrieved on: 
Thursday, August 6, 2020
Countries, Medical specialties, International organizations, Vaccination, Bio Farma, Indonesia, Polio, Vaccine

"BUMN launched its Go Global program to support Indonesia's Supply Chain in marketing products in strategic markets.

Key Points: 
  • "BUMN launched its Go Global program to support Indonesia's Supply Chain in marketing products in strategic markets.
  • In addition, Bio Farma has produced and marketed polio vaccines in various countries such as Angola, Somalia and Ethiopia.
  • "Strike while the iron is hot: taking advantage of the moment, when the momentum is right in Indonesia."
  • Moreover, this collaboration is further fortified by an aggressive strategy which ensures that every step taken promotes Indonesian competitiveness in an increasingly fierce global market.

DENSO, Global Mobility Service to Support Delivery of COVID-19 Test Kits in Indonesia

Retrieved on: 
Monday, May 18, 2020
Natural sciences, Laboratory techniques, Molecular biology, Physical sciences, Branches of biology, Biotechnology, Amplifiers, Polymerase chain reaction, Bio Farma

Health care workers in Indonesia have relied on imported PCR test kits to trace and fight the virus, but growing demand has caused a shortage of these critical tests.

Key Points: 
  • Health care workers in Indonesia have relied on imported PCR test kits to trace and fight the virus, but growing demand has caused a shortage of these critical tests.
  • was launched to mass-produce 100 thousand PCR testing kits in Indonesia.
  • In this project, Bio Farma, an Indonesian state-run pharmaceutical company, has already started mass production of PCR test kits.
  • (2) Mobility Service Platform is a platform system that performs management, control, data analysis, etc.

Batavia Biosciences receives $6.5M grant to take next step towards polio-free world

Retrieved on: 
Monday, September 16, 2019
Bio Farma, Vaccine

Chris Yallop, CSO of Batavia Biosciences, explains: The nOPV2 vaccine, provided by our partner Bio Farma, is currently the most advanced in clinical development and most in demand.

Key Points: 
  • Chris Yallop, CSO of Batavia Biosciences, explains: The nOPV2 vaccine, provided by our partner Bio Farma, is currently the most advanced in clinical development and most in demand.
  • The platform combines Univercells NevoLine manufacturing technology with Batavia Biosciences Highly Intensified Process ( HIP -Vax) technology for viral vaccines.
  • Menzo Havenga, CEO of Batavia Biosciences, comments: We are very excited to work with these eminent partners and take the next step towards a polio-free world.
  • Headquartered in Leiden, the Netherlands, with a subsidiary in Woburn, Massachusetts, and offices in Hong Kong, Batavia Biosciences is privileged to have strong strategic partners worldwide.

Indonesia's Medicine Regulator Holds the First Meeting of the Heads of NMRAs of OIC Countries Towards Medicines and Vaccines Self Reliance

Retrieved on: 
Friday, November 23, 2018
Bio Farma, Vaccine, Organisation of Islamic Cooperation

The diverse condition of political and economies in OIC member states made several limitation of access towards medicine and vaccines in some of OIC member states.

Key Points: 
  • The diverse condition of political and economies in OIC member states made several limitation of access towards medicine and vaccines in some of OIC member states.
  • Moreover, infectious diseases are still a big problem for a number of the OIC member states.
  • Indonesia through Bio Farma has exported vaccines to 141 countries, including 49 OIC member states.
  • In terms of vaccines production capabilities, Indonesia is one of leading countries among member of OIC.